Disclaimer: This article has been developed and funded by Daiichi Sankyo. Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market ...

AstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, worth up to $6 billion. The deal covers DS-1062, Daiichi Sankyo’s proprietary ...

BASKING RIDGE, N.J. & RAHWAY, N.J., May 29, 2025--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A total of 73 patients diagnosed with LM were treated with osimertinib, including 64 patients evaluable for the LM efficacy set—T790M negative (n = 62) and T790M positive (n = 2). The median OS in the ...

The Career Fair offers a convenient way for attendees to explore available career options with representatives from hospitals, academic institutions, private practices, and leading firms in the field ...

The 2025 ASCO Annual Meeting will be in-person and online, May 30 - June 3, 2025. Become an exhibitor and reach more than 36,400 health care professionals from around the world. Over 400 organizations ...

The initial abstract must be submitted by the January 28, 2025 deadline as a placeholder (shell) abstract submission. During submission, you will be required to enter all authors and their disclosures ...